Autologous Peripheral Blood Stem Cell Transplantation in Children with Refractory or Relapsed Lymphoma: Results of Children’s Oncology Group Study A5962
| Autor: | James C. Lynch, Lynette M. Smith, Phyllis I. Warkentin, Adrianna Vlachos, Michael M. Henry, Lauren Harrison, Thomas G. Gross, Mitchell S. Cairo, Sherrie L. Perkins, Amanda Termuhlen, Richard E. Harris |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Lung Diseases
Male Oncology Autologous transplant Transplantation Conditioning Lymphoma HL Salvage therapy 0302 clinical medicine Recurrence Antineoplastic Combined Chemotherapy Protocols Child Etoposide Lymphoma Non-Hodgkin Remission Induction Hematology Hodgkin Disease Hematopoietic Stem Cell Mobilization 3. Good health Child Preschool 030220 oncology & carcinogenesis Female medicine.drug medicine.medical_specialty Adolescent Cyclophosphamide CBV NHL Transplantation Autologous Article Young Adult 03 medical and health sciences Refractory Internal medicine medicine Humans PBSCT Salvage Therapy Peripheral Blood Stem Cell Transplantation Transplantation Carmustine business.industry medicine.disease Drug Resistance Neoplasm business 030215 immunology |
| Zdroj: | Biology of Blood and Marrow Transplantation. 17:249-258 |
| ISSN: | 1083-8791 |
| Popis: | This prospective study was designed to determine the safety and efficacy of cyclophosphamide, BCNU, and etoposide (CBV) conditioning and autologous peripheral blood stem cell transplant (PBSCT) in children with relapsed or refractory Hodgkin and non-Hodgkin lymphoma (HL and NHL). Patients achieving complete remission (CR) or partial remission (PR) after 2 to 4 courses of reinduction underwent a granulocyte-colony stimulating factor (G-CSF) mobilized PBSC apheresis with a target collection dose of 5 × 106 CD34+/kg. Those eligible to proceed received autologous PBSCT after CBV (7200 mg/m2, 450-300 mg/m2, 2400 mg/m2). Forty-three of 69 patients (30/39 HL, 13/30 NHL) achieved a CR/PR after reinduction. Thirty-eight patients (28 HL, 10 NHL) underwent PBSCT. All initial 6 patients who received BCNU at 450 mg/m2 experienced grade III or IV pulmonary toxicity compared to none of the subsequent 32 receiving 300 mg/m2 (P < .0001). The probability of overall survival (OS) at 3 years for all patients is 51% and for transplanted patients is 64%. The 3-year event-free survival (EFS) is 38% (45% for HL; 30% NHL). The 3-year EFS in transplanted patients is 66% (65% HL; 70% NHL). Initial duration of remission of ≥12 versus |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect